Revealing Unpredicted Aspartic Acid Isomerization Hotspots by Probing Diagnostic Fragmentation Propensities in Top-Down and Middle-Down Mass Spectrometry
Journal of the American Society for Mass Spectrometry · 2025
DOI: 10.1021/jasms.4c00443 ↗At a glance
Journal article in Journal of the American Society for Mass Spectrometry, 2025. Written by Blandine Denefeld and 7 co-authors. Institution: Analytical Characterization, Biologics Analytical Development, Technical Research & Development, Novartis Pharma AG, WKL693.3.20, Postfach, CH-4002 B…. Major MEDLINE topics: Aspartic Acid, Mass Spectrometry. Cited 2 times so far (Crossref); 39 references. Funded by: Novartis Pharma.
Abstract (original language)
Isomerization of aspartic acid residues is a relevant degradation pathway of protein biopharmaceuticals as it can impair their biological activity. However, the in silico prediction of isomerization hotspots and their consequences remains ambiguous and misleading. We have previously shown that all ion differential analysis (AiDA) of middle-down spectra can be used to reveal diagnostic terminal and internal fragments with more sensitivity than the conventional fragment ion mass matching methodology. In this study, we use AiDA to characterize the degradation of an antibody fragment at three aspartic acid isomerization sites including a novel DW motif directly with electron-transfer/higher-energy collisional dissociation top-down and middle-down mass spectrometry. We show that AiDA methodology is pivotal to probe diagnostic fragmentation propensities of terminal c and z fragments at the N-terminus and vicinity of isomerization sites in addition to the diagnostic c+57 terminal fragments. Furthermore, AiDA can probe remote structural changes in the loop of an antibody complementarity-determining region induced by isomerization and the succinimide intermediate, revealing interactions between residues in agreement with molecular simulations. This study shows that aspartic acid residues at noncanonical DW and DF motifs can be hotspots for isomerization despite being ranked as false positives in physics-based prediction models. We show that the enzyme-free, fast, and sensitive AiDA methodology can be used as an orthogonal technique to fractionation for online variant characterization.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Analytical Characterization, Biologics Analytical Development, Technical Research & Development, Novartis Pharma AG, WKL693.3.20, Postfach, CH-4002 Basel, Switzerland.
- Structure-Biophysics-Stability, Biologics Drug Product Development, Technical Research & Development, Novartis Pharmaceutical Manufacturing LLC, Kolodvorska 27, SI-1234 Mengeš, Slovenia.
- Protein Sciences, Discovery Sciences, Novartis Biomedical Research, Virchow 16, CH-4056 Basel, Switzerland.
ORCID profiles: Jean-Michel Rondeau, François Griaud
Funding
- Novartis Pharma
Cite
APA
Denefeld, B., Hajduk, J., Cerar, J., Rondeau, J. M., Dayer, J., Lang, M., Kern, W., & Griaud, F. (2025). Revealing Unpredicted Aspartic Acid Isomerization Hotspots by Probing Diagnostic Fragmentation Propensities in Top-Down and Middle-Down Mass Spectrometry. Journal of the American Society for Mass Spectrometry. https://doi.org/10.1021/jasms.4c00443
Vancouver
Denefeld B, Hajduk J, Cerar J, Rondeau JM, Dayer J, Lang M, et al. Revealing Unpredicted Aspartic Acid Isomerization Hotspots by Probing Diagnostic Fragmentation Propensities in Top-Down and Middle-Down Mass Spectrometry. Journal of the American Society for Mass Spectrometry. 2025. doi:10.1021/jasms.4c00443
BibTeX
@article{Denefeld2025,
author = {Denefeld, Blandine and Hajduk, Joanna and Cerar, Jure and Rondeau, Jean-Michel and Dayer, Jérôme and Lang, Manuel and Kern, Wolfram and Griaud, François},
title = {Revealing Unpredicted Aspartic Acid Isomerization Hotspots by Probing Diagnostic Fragmentation Propensities in Top-Down and Middle-Down Mass Spectrometry},
journal = {Journal of the American Society for Mass Spectrometry},
year = {2025},
doi = {10.1021/jasms.4c00443}
}
EUVIMED